PROJECT NARRATIVE: Human T cell Leukemia Virus type-1 (HTLV-1) is a human retrovirus that is the causative agent of a malignant CD4+ T cell lymphoproliferation referred to as Adult T cell leukemia/lymphoma (ATLL), as well as several inflammatory disorders with the most problematic being human myelopathy/tropical spastic paraparesis (HAM/TSP). Remarkably, while millions are affected worldwide, there are no effective vaccines to prevent associated disease or treatment options for ATLL or HAM/TSP afflicted individuals. We thus aim here, to develop a candidate vaccine to prevent and plausibly treat HTLV-1-associated disease.
|Effective start/end date||2/1/22 → 1/31/23|
- National Institute of Allergy and Infectious Diseases: $299,860.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.